News

Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump

Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planningNEW YORK,…

11 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune…

11 months ago

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025…

11 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a…

11 months ago

Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation

One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network Polarean and SimonMed…

11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to…

11 months ago

FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus…

11 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with…

11 months ago

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March…

11 months ago

Lighthouse Autism Center Announces New Location in South Sioux City, Nebraska, creating 35 Jobs and Serving 25 Families

Leading ABA Provider Set to Open Newest Location in South Sioux City, NE Therapy Room at LAC Therapy Room at…

11 months ago